All In Biotech

Drug Trial Radar · NCT00314158

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Last checked: Nov 20, 2026Latest source record: Nov 18, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 523 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

523

Actual

Start

Nov 2005

Primary completion

Jan 2007

Study completion Jan 2007

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Apr 13, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.

Conditions

  • Open-angle Glaucoma
  • Ocular Hypertension

Interventions

  • Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspensionDrug

    One drop twice daily in each study eye for six months

  • Brinzolamide 10 mg/ml (AZOPT) eye drops, suspensionDrug

    One drop twice daily in each study eye for six months

  • Timolol 5 mg/ml eye drops, solutionDrug

    One drop twice daily in each study eye for six months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean intra-ocular pressure (IOP)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • United States Investigative Sites

    Fort Worth, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.